China Yongxin Pharmaceuticals Inc. (CYXN.OB) Reports Higher Revenue and Net Income for First Quarter of 2010
China Yongxin Pharmaceuticals Inc. reported net income of $2.35 million, or $0.04 per diluted share, for the first quarter of…
Blog
EcoBlu Products, Inc. (ECOB.OB) Video Chart for Tuesday, May 25, 2010
ECOB made a nice move yesterday. Resistance from the 200dma is right ahead, but we are looking for a push…
General Environmental Management Inc. (GEVI.OB) Reports First Time Profitability with First Quarter 2010 Financial Results
Yesterday after the closing bell, General Environmental Management Inc. (GEM) announced its financial results for the three months ended March…
Newport Digital Technology, Inc. (NPDT.OB) Announces Introduction of RFID Products Compliant with Secure RFID Protocol
Newport Digital Technologies, Inc. announced early this morning that they have introduced Secure RFID Protocol compliant reader-writer (RW), inlays, tags,…
Vasomedical Inc. (VASO.OB) Up 80% Following Mention in QualityStocks Newsletter
Vasomedical Inc. closed today's trading at $0.21 a share, up $0.6 or 40% for the day. The upsurge in price…
National Automation Services, Inc. (NASV.PK) Increases Industrial and Technical Diversity
National Automation Services Inc., rapidly solidifying its position as a national leader in advanced automation and control systems solutions, is…
Consorteum Holdings, Inc. (CSRH.OB) Recently Announced Initiative for Streamlined Efficiency
Consorteum Holdings Inc. has extensive expertise within the payments and transaction industry globally. By identifying new technologies and trends in…
NanoViricides, Inc. (NNVC.OB) Files Quarterly Report with SEC
Nanoviricides Inc. is a development stage company creating special purpose nanomaterials for viral therapy. The company's novel nanoviricide class of…
Image Metrics Inc. (IMGX.OB) Posts Solid Q2 Results, Gives Future Expectations
Image Metrics Inc., a provider of facial animation software and services for the entertainment and film industry, today posted its…
Pro-Pharmaceuticals, Inc. (PRWP.OB) Announces Plans to Submit Phase III Trial Design to FDA
Pro-Pharmaceuticals Inc. engages in the discovery, development and commercialization of advanced treatment of cancer and fibrosis. The company today said…